/Companies

Mosanna Therapeutics

7 known investors

Find your way into Mosanna Therapeutics

Sign up to see every warm intro you have to Mosanna Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Mosanna Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Mosanna is a pharmaceutical company developing a non-invasive nasal spray therapy for obstructive sleep apnea (OSA) that reactivates the body's natural airway reflex to keep the upper airway open during sleep. Its lead candidate, MOS-118, is a small molecule delivered before bedtime that stimulates upper airway dilator muscles to reduce apnea and hypopnea episodes.

Founders & leadership

B
BarbaraRegulatory Affairs & Quality Assurance leadership
K
KevinPharmaceutical Development leadership
P
PranavHead of Finance & Operations
B
BenExecutive / Board

Board

DW
David WhiteSleep Medicine Advisor

Investors · 7

Founder mafia

2 people who came through Mosanna Therapeutics went on to found or lead other companies.

In the news

Frequently asked questions

What does Mosanna Therapeutics do?
Mosanna is a pharmaceutical company developing a non-invasive nasal spray therapy for obstructive sleep apnea (OSA) that reactivates the body's natural airway reflex to keep the upper airway open during sleep. Its lead candidate, MOS-118, is a small molecule delivered before bedtime that stimulates upper airway dilator muscles to reduce apnea and hypopnea episodes.
Who are Mosanna Therapeutics's investors?
Mosanna Therapeutics's investors include Broadview Ventures, Norwest Venture Partners, Pivotal Life Sciences, Supermoon Capital, Forbion, HTGF, Inkef.